{"id":62581,"date":"2026-02-02T16:06:18","date_gmt":"2026-02-02T15:06:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\/"},"modified":"2026-02-02T16:06:18","modified_gmt":"2026-02-02T15:06:18","slug":"red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\/","title":{"rendered":"Red Nucleus to Acquire Bridge Medical Consulting, Expanding Health Economics and Outcomes Research Capabilities"},"content":{"rendered":"
\n

\nDeal enhances existing value, evidence, and market access solutions as demand for economic and outcomes services accelerates<\/b><\/p>\n

YARDLEY, Pa.–(BUSINESS WIRE)–Red Nucleus, a leading provider of strategic services across research and development, medical affairs, market access, commercial, and learning & development, today announced that it has acquired Bridge Medical Consulting, a specialized health economics and outcomes research (HEOR) consultancy. The acquisition represents a key step in Red Nucleus\u2019s strategy, strengthening its ability to help biopharmaceutical companies demonstrate the clinical and economic value of increasingly specialized therapies in a complex regulatory and reimbursement environment and bolstering its current set of capabilities within HEOR.<\/p>\n

<\/a>
<\/a><\/p>\n

\nFounded in 2011, Bridge Medical Consulting is recognized for its expertise in evidence synthesis, integrated evidence planning, population insights, health economic modeling, and statistics, partnering with pharmaceutical and biotech clients across Europe and the United States. The firm brings deep scientific rigor, a global client base, and a differentiated approach that combines domain expertise with artificial intelligence\u2013enabled workflows to deliver decision-grade evidence at speed and scale.<\/p>\n

\n\u201cWith payers and regulators placing unprecedented scrutiny on drug pricing and value, HEOR has become mission-critical for life sciences companies,\u201d said Mike Menta, Chief Executive Officer of Red Nucleus. \u201cThis acquisition enhances our ability to support clients across value, evidence, and market access. Bridge Medical Consulting\u2019s expertise, culture, and forward-looking approach to technology make them an exceptional fit for Red Nucleus, and we\u2019re excited to welcome their team.\u201d<\/p>\n

\nSpecifically, the addition of Bridge Medical Consulting expands Red Nucleus\u2019s ability to support customers as they navigate evolving global requirements, including increased demand for real-world evidence, joint clinical assessments in Europe, and more rigorous value-based decision-making by health authorities worldwide. The combined organization will offer customers of both companies a more comprehensive, integrated approach spanning evidence synthesis (including systematic literature reviews (SLRs) and indirect treatment comparisons (ITCs)), evidence planning, evidence generation, economic modeling, statistics, RWE research, and strategic advisory.<\/p>\n

\n\u201cJoining Red Nucleus allows us to scale our impact and offer clients a broader, more integrated set of services,\u201d said Paul Gandhi, Founder and Chief Executive Officer of Bridge Medical Consulting. \u201cWe share a commitment to scientific excellence and to thoughtfully applying AI and related technologies to enhance rigor and efficiency, while keeping expert judgment at the center of our work. The combined platform brings together complementary expertise that will benefit customers of both companies.\u201d<\/p>\n

\nBridge Medical Consulting will be merged with Red Nucleus’s existing HEOR business under Monique Martin, Global Head of HEOR. \u201cI am very excited to partner with the brilliant Bridge Medical Consulting team who bring a range of HEOR capabilities to Red Nucleus. I have been particularly impressed by their robust and transparent approach to developing applied AI solutions, especially to decision-grade SLRs, combining the best of AI with the best of humans to yield the highest quality client outputs. From the high uptake of Bridge Medical\u2019s AI-enabled offerings, it is clear that clients also value this innovative, robust, and transparent approach,\u201d said Monique. HEOR is part of Red Nucleus’s broader, global Value & Evidence organization.<\/p>\n

\nAbout Red Nucleus
\n
<\/b>Red Nucleus (rednucleus.com<\/a><\/b>) is a global strategic partner with decades of experience across the entire life sciences product life cycle. The company excels in providing clients with unique insights and efficiencies to support their journey to improve health outcomes and ultimately the quality of people\u2019s lives. Red Nucleus\u2019 \u201cRed Thread\u201d weaves together a full suite of products and services from learning & development, scientific services & advisory, medical and scientific communications, and market access, which leads the company\u2019s life sciences customers to accelerated transformational success. With offices worldwide in seven countries, our commitment to quality and on-time delivery is unrivaled in the industry.<\/p>\n

\nAbout Bridge Medical Consulting
\n
<\/b>Bridge Medical Consulting is a specialized health economics and outcomes research consultancy supporting global pharmaceutical and biotechnology companies with evidence synthesis, integrated evidence planning, health economic modeling, statistics and other strategic HEOR services to inform regulatory, reimbursement, and market access decision-making.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contacts<\/b><\/p>\n

\nNicole Hakimi
\n
nicole.hakimi@edelmansmithfield.com<\/a><\/p>\n

\nMary Kilmartin
\n
mary.kilmartin@edelmansmithfield.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Deal enhances existing value, evidence, and market access solutions as demand for economic and outcomes services accelerates YARDLEY, Pa.–(BUSINESS WIRE)–Red Nucleus, a leading provider of strategic services across research and development, medical affairs, market access, commercial, and learning & development, today announced that it has acquired Bridge Medical Consulting, a specialized health economics and outcomes … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62581","6":"format-standard","7":"category-industry"},"yoast_head":"\nRed Nucleus to Acquire Bridge Medical Consulting, Expanding Health Economics and Outcomes Research Capabilities - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Red Nucleus to Acquire Bridge Medical Consulting, Expanding Health Economics and Outcomes Research Capabilities - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Deal enhances existing value, evidence, and market access solutions as demand for economic and outcomes services accelerates YARDLEY, Pa.–(BUSINESS WIRE)–Red Nucleus, a leading provider of strategic services across research and development, medical affairs, market access, commercial, and learning & development, today announced that it has acquired Bridge Medical Consulting, a specialized health economics and outcomes ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-02T15:06:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260202142734\/en\/2707981\/22\/RN_Logo_POS_TM_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Red Nucleus to Acquire Bridge Medical Consulting, Expanding Health Economics and Outcomes Research Capabilities\",\"datePublished\":\"2026-02-02T15:06:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\\\/\"},\"wordCount\":697,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260202142734\\\/en\\\/2707981\\\/22\\\/RN_Logo_POS_TM_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\\\/\",\"name\":\"Red Nucleus to Acquire Bridge Medical Consulting, Expanding Health Economics and Outcomes Research Capabilities - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260202142734\\\/en\\\/2707981\\\/22\\\/RN_Logo_POS_TM_RGB.jpg\",\"datePublished\":\"2026-02-02T15:06:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260202142734\\\/en\\\/2707981\\\/22\\\/RN_Logo_POS_TM_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260202142734\\\/en\\\/2707981\\\/22\\\/RN_Logo_POS_TM_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Red Nucleus to Acquire Bridge Medical Consulting, Expanding Health Economics and Outcomes Research Capabilities\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Red Nucleus to Acquire Bridge Medical Consulting, Expanding Health Economics and Outcomes Research Capabilities - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\/","og_locale":"en_US","og_type":"article","og_title":"Red Nucleus to Acquire Bridge Medical Consulting, Expanding Health Economics and Outcomes Research Capabilities - Pharma Trend","og_description":"Deal enhances existing value, evidence, and market access solutions as demand for economic and outcomes services accelerates YARDLEY, Pa.–(BUSINESS WIRE)–Red Nucleus, a leading provider of strategic services across research and development, medical affairs, market access, commercial, and learning & development, today announced that it has acquired Bridge Medical Consulting, a specialized health economics and outcomes ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\/","og_site_name":"Pharma Trend","article_published_time":"2026-02-02T15:06:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260202142734\/en\/2707981\/22\/RN_Logo_POS_TM_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Red Nucleus to Acquire Bridge Medical Consulting, Expanding Health Economics and Outcomes Research Capabilities","datePublished":"2026-02-02T15:06:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\/"},"wordCount":697,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260202142734\/en\/2707981\/22\/RN_Logo_POS_TM_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\/","url":"https:\/\/pharma-trend.com\/en\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\/","name":"Red Nucleus to Acquire Bridge Medical Consulting, Expanding Health Economics and Outcomes Research Capabilities - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260202142734\/en\/2707981\/22\/RN_Logo_POS_TM_RGB.jpg","datePublished":"2026-02-02T15:06:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260202142734\/en\/2707981\/22\/RN_Logo_POS_TM_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260202142734\/en\/2707981\/22\/RN_Logo_POS_TM_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/red-nucleus-to-acquire-bridge-medical-consulting-expanding-health-economics-and-outcomes-research-capabilities\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Red Nucleus to Acquire Bridge Medical Consulting, Expanding Health Economics and Outcomes Research Capabilities"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62581"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62581\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}